Alicia Morgans, MD, MPH, Discusses Outcomes From the CARD Trial in mCRPC at 2021 ESMO

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.

At the 2021 European Society of Medical Oncology Congress, CancerNetwork® spoke with Alicia Morgans, MD, MPH, director of the Survivorship Program at Dana-Farber Cancer Center, about the progression and survival outcomes patient patients with metastatic castration-resistant prostate cancer at different time points throughout the phase 4 CARD trial (NCT02485691). Patients who enrolled on the trial were treated with either cabazitaxel (Jevtana) or a second androgen receptor inhibitor such as abiraterone (Zytiga) or enzalutamide (Xtandi) in order to compare costs and complications.

Transcript:

Interestingly, we found over time that the outcomes changed such that shorter term outcomes, [such as] progression decreased over the course of the study because at some point, patients did experience progression. The survival outcomes increased by the end of our follow-up period, as we really solidified mortality for some patients who had those unfortunate events. Ultimately, the reason we chose 18 months is that it was a nice time point to try to get a balanced picture. Between the 6-month shorter time points, and then our longer-term time points, it was just a nice place to report our primary findings.

Reference

Morgans AK, Hutson TE, Guan AK, et al. Clinical and cost impact of cabazitaxel versus (vs) a second androgen receptor targeted agent (ARTA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and the alternative ARTA (abiraterone or enzalutamide). Presented at: 2021 European Society of Medical Oncology Congress; September 16-21, 2021; Virtual. Abstract 587P.